Calamos Select Fund C holds a quantitatively derived Neutral Morningstar Medalist Rating. The rating suggests the model does not express a clear expectation of outperformance or underperformance relative to peers over a full market cycle.
Calamos Select Fund Class C CVACX
- NAV / 1-Day Return 18.60 / −2.36 %
- Total Assets 62.6M
-
Adj. Expense Ratio
1.900%
- Expense Ratio 1.900%
- Distribution Fee Level High
- Share Class Type Level Load
- Category Large Blend
- Investment Style Large Blend
- Min. Initial Investment 2,500
- Status Open
- TTM Yield 0.00
- Turnover 46%
USD | NAV as of Jun 06, 2026 | 1-Day Return as of Jun 06, 2026, 1:05 AM GMT+0
Morningstar’s Analysis CVACX
Will CVACX outperform in the future?
Get our overall rating based on a fundamental assessment of the pillars below.
People Pillar
The People Pillar is our evaluation of the CVACX management team’s experience and ability. We find that high-quality management teams deliver superior performance relative to their benchmarks and/or peers.
Parent Pillar
The Parent Pillar is our rating of CVACX’s parent organization’s priorities and whether they’re in line with investors’ interests.
- Current Portfolio Date
- Equity Holdings —
- Bond Holdings —
- Other Holdings —
- % Assets in Top 10 Holdings 46.5
|
Top 10 Holdings
|
% Portfolio Weight
|
Market Value USD
|
Sector
|
|---|---|---|---|
Alphabet Inc Class A | 7.58 | 4M | Communication Services |
NVIDIA Corp | 7.54 | 4M | Technology |
Apple Inc | 7.02 | 4M | Technology |
Amazon.com Inc | 5.71 | 3M | Consumer Cyclical |
Microsoft Corp | 5.12 | 3M | Technology |
Broadcom Inc | 3.65 | 2M | Technology |
Meta Platforms Inc Class A | 2.78 | 2M | Communication Services |
Chevron Corp | 2.55 | 1M | Energy |
Johnson & Johnson | 2.37 | 1M | Healthcare |
Eli Lilly and Co | 2.21 | 1M | Healthcare |
United States